Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01831466 · ClinicalTrials.gov registry record · Phase 2

Tofacitinib Ointment For Chronic Plaque Psoriasis

A Phase 2 study, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
476
Enrollment target

NCT01831466 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 476 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01831466, a Phase 2 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
476 participants
Enrollment target

Study Summary

The study is beng done to test if tofacitinib ointment is safe and effective for people with plaque psoriasis. Two dose strengths of tofacitinib ointment (20 mg/g and 10 mg/g) applied once or twice daily are being tested. The safety and effectiveness of tofacitinib ointment used for 12 weeks will be compared to the safety and effectiveness of placebo ointment (vehicle) used for 12 weeks.

Interventions

  • DRUG tofacitinib ointment 20 mg/g
  • DRUG tofacitinib ointment 10 mg/g
  • DRUG placebo ointment (vehicle)

Trial Details

FieldValue
Enrollment Target 476 participants
Start Date 2013-05
Est. Completion 2014-09
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT01831466

The ClinicalTrials.gov registry entry for NCT01831466 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 476 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which tofacitinib ointment 20 mg/g is the first listed.

NCT01831466 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01831466 about?

NCT01831466 is a clinical study titled "Tofacitinib Ointment For Chronic Plaque Psoriasis". The study is beng done to test if tofacitinib ointment is safe and effective for people with plaque psoriasis. Two dose strengths of tofacitinib ointment (20 mg/g and 10 mg/g) applied once or twice daily are being tested. The safety and effectiveness of tofacitinib ointment used for 12 weeks will be...

What is the current status of trial NCT01831466?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 476 participants. The study started on 2013-05. Estimated completion is 2014-09.

What interventions are being tested in trial NCT01831466?

The interventions under investigation include: tofacitinib ointment 20 mg/g (DRUG), tofacitinib ointment 10 mg/g (DRUG), placebo ointment (vehicle) (DRUG).

Who is sponsoring clinical trial NCT01831466?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.